Our focus in the clinic is on advancing our lead candidate, berberine ursodeoxycholate (HTD1801), in chronic metabolic diseases. Based on its dual mechanism of action we are particularly focused on diseases driven by insulin resistance and chronic inflammation. In addition to our lead candidate, we have a growing discovery portfolio.
HighTide’s mission is to identify the unmet needs in these inter-related chronic metabolic diseases and translate those needs into new therapeutic solutions.
June 27, 2025
ADA 2025 | HighTide Therapeutics Announces Late-Breaking Presentation of Phase 3 SYMPHONY 1 Data in Patients with Type 2 Diabetes
May 6, 2025
HighTide Therapeutics Presents Preclinical Results of Rimtoregtide (HTD4010) in Presentation at Digestive Disease Week® 2025
April 22, 2025
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025